Physicians' Academy for Cardiovascular Education

Incidence of new-onset diabetes reduced by SGLT2 inhibitor

Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials

Literature - Rossing P, Inzucchi SE, Vart P et al., - Lancet Diabetes Endocrinol. 2022;10(1):24-34. doi: 10.1016/S2213-8587(21)00295-3.

Introduction and methods


There is a need for effective and safe treatment to prevent diabetes and its complications. SGLT2 inhibitors were initially developed as glucose-lowering therapy for patients with type 2 diabetes (T2DM). Trials have demonstrated that these agents reduce risk of adverse CV events and kidney outcomes n T2DM patients. In addition, treatment with the SGLT2 inhibitors empagliflozin and dapagliflozin resulted in cardiorenal benefits in patients with heart failure or chronic kidney disease [1,2].

In this prespecified analysis of the DAPA-CKD trial and the DAPA-HF trial, pooled individual patient-level data were used to examined the effects of dapagliflozin on new-onset T2DM and the association with baseline characteristics was explored.

Study design

Data from DAPA-CKD and DAPA-HF trials were pooled. This analysis included 4003 participants who did not have T2DM at baseline (no previous diagnosis of T2DM or HbA1c ≥6.5%). Patients were classified as having prediabetes (HbA1c between 5.7%-6.4%) or normoglycemia (HbA1c <5.7%). Patients with randomized (1:1) to dapagliflozin or placebo. Median follow-up was 21.2 months (IQR 16.0-25.4).

Main outcomes

Incidence of a new diagnosis of T2DM was a prespecified exploratory endpoint.

Main results


This prespecified exploratory analysis of pooled data from the DAPA-CKD and DAPA-HF trials showed that in patients without T2DM at baseline, dapagliflozin reduced the incidence of new-onset T2DM.


Show references

Find this article online at Lancet Diabetes Endocrinol

Share this page with your colleagues and friends: